Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplemental figure A FA-D2 +FANCD2 FA-D2 +FANCD2(K561R) No HU 0.1mM HU S phase: 43%S phase: 34.7% S phase: 30.8% S phase: 52.7%S phase: 25.4%S phase:

Published byMiranda Murphy Modified over 9 years ago

Similar presentations

Presentation on theme: "Supplemental figure A FA-D2 +FANCD2 FA-D2 +FANCD2(K561R) No HU 0.1mM HU S phase: 43%S phase: 34.7% S phase: 30.8% S phase: 52.7%S phase: 25.4%S phase:"— Presentation transcript:

1 Supplemental figure A FA-D2 +FANCD2 FA-D2 +FANCD2(K561R) No HU 0.1mM HU S phase: 43%S phase: 34.7% S phase: 30.8% S phase: 52.7%S phase: 25.4%S phase: 21.9%

2 Supplemental figure B Input IgG FlagAb IP Rad18 Rad51 FACND2 Blot: 1 2 3

3 Supplemental figure C - HU Whole cell Blot: CRad51siRNA - HU Chromatin Blot: CRad51siRNA Rad51 Ku86 USP1 Rad51 Ku86 USP1 1 2 3 4

4 Supplemental figure D Blot: - MMC HU - MMC HU - MMC HU Chromatin Rad51-7Rad51-2siRNAC Blot: - MMC HU - MMC HU - MMC HU Chromatin FANCD2-18FANCD2-2siRNAC PCNA Ku86 Ub-PCNA Ku86 PCNA Ub-PCNA FANCD2 Blot: - MMC HU - MMC HU - MMC HU Whole cell Rad51-7Rad51-2siRNAC Blot: - MMC HU - MMC HU - MMC HU Whole cell FANCD2-18FANCD2-2siRNAC Rad51 Ku86 FANCD2 PCNA Rad51 Ku86 FANCD2 PCNA

5 Supplemental figure D (continued) Blot: - MMC HU - MMC HU - MMC HU - MMC HU - MMC HU Soluble FANCD2-18 FANCD2-2 siRNAC Rad51-7Rad51-2 PCNA Ku86 FANCD2 PCNA Long exposure

6 Supplemental figure E PCNA Ku86 - HU DMSOB02 DMSO B02 Whole cell Chromatin Blot: - HU PCNA Ku86 Blot: Ub-PCNA

7 Supplemental figure F PCNA Ku86 - HU BRCA2-/-BRCA2+/+ BRCA2-/- BRCA2+/+ Whole cell Chromatin Blot: - HU PCNA Ku86 Blot: Ub-PCNA

8 Supplemental figure G Blot: - MMC HU - MMC HU - MMC HU - MMC HU - MMC HU Chromatin FANCD2-18 FANCD2-2 siRNAC Rad51-7Rad51-2 Blot: - MMC HU - MMC HU - MMC HU - MMC HU - MMC HU Whole cell FANCD2-18 FANCD2-2 siRNAC Rad51-7Rad51-2 PolH Ku86 FANCD2 Rad51 Ku86 FANCD2 PolH

9 Supplemental figure H Ku86 Blot: Rad51 siRNAC 7 2 Rad51

Download ppt "Supplemental figure A FA-D2 +FANCD2 FA-D2 +FANCD2(K561R) No HU 0.1mM HU S phase: 43%S phase: 34.7% S phase: 30.8% S phase: 52.7%S phase: 25.4%S phase:"

Similar presentations

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.
Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.
1.96E+07 3.9E+07 6.6 E+07 3.4E+07 6.7E+07 5.7E+07 0E+0 1E+7 2E+7 3E+7 4E+7 5E+7 6E07 7E+7 8E+7 9E+7 hWASP1 Cell Growth 234234 Cell Number Days of Growth.

1.96E E E E E E+07 0E+0 1E+7 2E+7 3E+7 4E+7 5E+7 6E07 7E+7 8E+7 9E+7 hWASP1 Cell Growth Cell Number Days of Growth.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Presented by Stella Snyder

Presented by Stella Snyder
Phase Difference = 0.00. Phase Difference = 0.05.

Phase Difference = Phase Difference = 0.05.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
-11.9 kb -4.2 kb -5.6 kb Gfi1 +/1b neo Gfi1 +/+ Gfi1 +/1b Gfi1 1b/1b Gfi1 +/1b Gfi1 +/+ -11.9 kb - 4.2 kb Gfi1 +/+ Gfi1 +/1b -14 kb - 8 kb B A Gfi1 +/+

-11.9 kb -4.2 kb -5.6 kb Gfi1 +/1b neo Gfi1 +/+ Gfi1 +/1b Gfi1 1b/1b Gfi1 +/1b Gfi1 +/ kb kb Gfi1 +/+ Gfi1 +/1b -14 kb - 8 kb B A Gfi1 +/+
Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1.

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b
The reading is 7.38 mm. The reading is 7.72 mm.

The reading is 7.38 mm. The reading is 7.72 mm.
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Cdc5L is required for the activation of ATR‐mediated checkpoint pathways. Cdc5L is required for the activation of ATR‐mediated checkpoint pathways. (A,B)

Cdc5L is required for the activation of ATR‐mediated checkpoint pathways. Cdc5L is required for the activation of ATR‐mediated checkpoint pathways. (A,B)
Transfer of preformed ubiquitin chains by Rad6–Rad18 and Ubc13–Mms2–Rad5. Transfer of preformed ubiquitin chains by Rad6–Rad18 and Ubc13–Mms2–Rad5. Abbreviations.

Transfer of preformed ubiquitin chains by Rad6–Rad18 and Ubc13–Mms2–Rad5. Transfer of preformed ubiquitin chains by Rad6–Rad18 and Ubc13–Mms2–Rad5. Abbreviations.
Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair by Luca Colnaghi, Mathew.

Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair by Luca Colnaghi, Mathew.
Volume 11, Issue 1, Pages (April 2015)

Volume 11, Issue 1, Pages (April 2015)
NON-DIVIDING PHASE EX: nerve cell Cell STOPS dividing G1 S G2 COPY DNA

NON-DIVIDING PHASE EX: nerve cell Cell STOPS dividing G1 S G2 COPY DNA
Volume 14, Issue 4, Pages (May 2004)

Volume 14, Issue 4, Pages (May 2004)
Deubiquitination of FANCD2 Is Required for DNA Crosslink Repair

Deubiquitination of FANCD2 Is Required for DNA Crosslink Repair
Supplemental Figure S1 a b

Supplemental Figure S1 a b
Supplemental Figure S2: G2 arrest in MCF7-shPBK1 stable cell line

Supplemental Figure S2: G2 arrest in MCF7-shPBK1 stable cell line

Similar presentations

Ads by Google